Fas Expression Prevents Cholangiocarcinoma Tumor Growth

Journal of Gastrointestinal Surgery

Volumn 3, Issue 4, 1999, Pages 374-382

  Pickens, Allan ^a   Pan, George ^b   McDonald, Jay M ^b   Vickers, Selwyn M ^a,c  

^a Kentucky   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apoptosis; CD95; Cholangiocarcinoma; Fas

Indexed keywords

COLORING AGENT; DIAGNOSTIC AGENT; FAS ANTIGEN; FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; KERATIN; LIGAND; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; TRYPAN BLUE;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BILE DUCT CARCINOMA; CANCER TRANSPLANTATION; CELL COUNT; CELL CULTURE; CELL SEPARATION; CELL SURVIVAL; COMPARATIVE STUDY; FLOW CYTOMETRY; GENETICS; HUMAN; MOUSE; NICK END LABELING; NUDE MOUSE; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; SKIN TUMOR; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTIGENS, SURFACE; APOPTOSIS; CELL COUNT; CELL SEPARATION; CELL SURVIVAL; CHOLANGIOCARCINOMA; COLORING AGENTS; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; KERATINS; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TRYPAN BLUE; TUMOR CELLS, CULTURED;

EID: 0033155822     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(99)80053-5     Document Type: Article

References (33)

1. Perry RR, Kang Y, Greaves B. Effect of tamoxifen on growth and apoptosis of estrogen dependent and independent human breast cancer cells. Ann Surg Oncol 1995;2:238-245.
2. Kang Y, Cortina R, Perry RR. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer. J Natl Cancer Inst 1996;88:279-284.
3. Frankfurt OS, Sugarbaker EV, Robb JA, et al. Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett 1995;97:149-154.
4. Love RR. Tamoxifen therapy in primary breast cancer: Biology, efficacy, and side effects. J Clin Oncol 1989;7:813-815.
5. Butta A, Maclennan K, Flanders KC, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992;52:4261-4264.
6. Sampson LK, Vickers SM, Ying W, et al. Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. Cancer Res 1997;57:1574-1579.
7. Taylor OM, Benson EA, McMahon MJ. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshine Gastrointestinal Tumor Group. Br J Surg 1993;80:384-386.
8. Pollack IF, Randall MS, Kristofik MP, et al. Effects of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 1990;50:7134-7138.
9. Couldwell WT, Weiss MH, DiGiorgio LM, et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 1993;32:485-490.
10. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 1997;24(Suppl 1):65-70.
11. Ward RL, Morgan G, Dalley D, et al. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 1993;22: 87-94.
12. Recker RR. Clinical review 41: Current therapy for osteoporosis [review]. J Clin Endocrinol Metab 1993;76:14-16.
13. Stanton MJ, Gaffney EF. Apoptosis: Basic concepts and potential significance in human cancer. Arch Pathol Lab Med 1998;122:310-319.
14. Pan ZQ, Radding W, Zhau T, et al. Role of calmodulin in HIV-potentiated Fas-mediated apoptosis. Am J Pathol 1996; 149:903-910.
15. Laine J, Etelamaki P, Holmberg C, Dunkel C. Apoptotic cell death in human chronic renal allograft rejection. Transplantation 1997;63:101-105.
16. Bellamy COC, Malcomson R, Wyllie AH. The role of p53 in apoptosis and cancer. In Martin SJ, ed. Apoptosis and Cancer. Basel: Karger Landes Systems, 1997, pp 132-133.
17. Wu JX. Apoptosis and angiogenesis: Two promising tumor markers in breast cancer [review]. Anticancer Res 1996;16: 2233-2240.
18. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
19. Trauth BC, Klas C, Peter AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-305.
20. Dhein J, Daniel PT, Trauth BC, et al. Induction of apoptosis by monoclonal anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 1992;149:3166-3173.
21. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor super-family in normal and neoplastic cells. Lab Invest 1993;69: 415-429.
22. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996;56:3870-3874.
23. Pan ZQ, Radding W, Zhou T, et al. Role of calmodulin in HIV-potentiated Fas-mediated apoptosis. Am J Pathol 1996;149:903-910.
24. Kawamura K, Grabowski D, Krivacic K, et al. Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes: Role for effects on apoptosis, DNA cleavable complex, and phosphorylation. Biochem Pharmacol 1996;52:1903-1909.
25. Nagata S, Golstein P. The Fas death factor. Science 1995;267: 1449-1456.
26. Inbal B, Cohen O, Polak-Charcon S, et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997;390:180-184.
27. Itoh N, Yonehara S, Ishii A, et al The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-243.
28. Melino G, Annicchiarico-Petruzzeli M, Piredda L, et al. Tissue transglutaminase and apoptosis: Sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol 1994;14:6584-6596.
29. Martinez-Lorenzo MJ, Alava MA, Anel A, et al. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology 1996;89:511-517.
30. Mori T, Xu JP, Mori E, et al. Expression of Fas-ligand system associated with atresia through apoptosis in murine ovary. Horm Res 1997;48(Suppl 3):11-19.
31. Wilson SE, Li Q, Weng J, et al. The Fas-Fas ligand system and other modulators of apoptosis in the cornea. Invest Ophthalmol Vis Sci 1996;37:1582-1592.
32. Martinez-Lorenzo MJ, Alava MA, Anel A, et al. Release of performed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology 1996;89:511-517.
33. Pan G, Vickers SM, Pickens A, et al. Apoptosis and tumorigenesis in human cholangiocarcinoma cells: Involvement of Fas/APO-1 (CD95) and calmodulin. Am J Pathol (in press).